FDA reviewing Astellas' AML candidate gilteritinib

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE